Longer follow-up confirms relapse-free survival benefit with adjuvant dabrafenib plus trametinib in patients with resected BRAF V600–mutant stage III melanoma

Axel Hauschild, Reinhard Dummer, Dirk Schadendorf, Mario Santinami, Victoria Atkinson, Mario Mandalà, Vanna Chiarion-Sileni, James Larkin, Marta Nyakas, Caroline Dutriaux, Andrew Haydon, Caroline Robert, Laurent Mortier, Jacob Schachter, Thierry Lesimple, Ruth Plummer, Kohinoor Dasgupta, Tomas Haas, Mark Shilkrut, Eduard GasalRichard Kefford, John M. Kirkwood, Georgina V. Long*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

192 Citations (Scopus)
34 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Longer follow-up confirms relapse-free survival benefit with adjuvant dabrafenib plus trametinib in patients with resected BRAF V600–mutant stage III melanoma'. Together they form a unique fingerprint.

Medicine & Life Sciences